Additionally, the potential of TYRP1 as a therapeutic target is being explored in a clinical trial testing RO7293583, an investigational drug for TYRP1-positive unresectable metastatic melanomas (NCT04551352). Here, TYRP1 is linked to metastatic melanoma.